ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Proposed Drug Act Revisions Would Provide Quick Approval Of “Breakthroughs,” IND_NDA Changes

March 24, 1978

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

NRC Group Splits Over chemical Dose Testing For Carcinogenicity

March 12, 1993

NCAB Grants Three MERIT Awards; Rimer To Leave NCI For Post At UNC

June 21, 2002

Contracting Dispute and Software Bugs Plague NCI’s $200 Million Bioinformatics Venture

February 25, 2011

ACCC To Ask Congress To Earmark Appropriations For Construction Of Community Cancer Centers

January 17, 1975